i agree, they are only doing it in hopes that if the gods are watching, that he will lean toward them , but lets get realm they just want the money
and not pretending to care about anything else? let's be real here folks
Wow, altho that makes me feel good, it also has me worried a bit? What makes all these people so confident? or are they hedging their bet somehow?
I lost a lot of money investing over the years, and this is my one shot at doubling and tripling my money to make up for my losses. Please approve this drug, I beg of you1
i couldnt care less about thsoe issues. as long as its some type of approval, there will be an immediate pop, at least double and then i can get out, and then the avg joe sucker can take care of the insurance thing
The vote was 6-7 against, BUT-
The committee should have instead focused on reviewing the drug in the context of a law passed in 2012 called the Food and Drug Administration Safety and Innovation Act, or FDASIA. It included multiple provisions to address the challenges of the rare disease patient community. In addition to having far fewer potential participants for drug studies, many rare diseases such as Duchenne are also 100 percent fatal, which means there are ethical concerns with giving any participant in a study a placebo.
One of the committee members who voted against the drug was later quoted as saying, “Based on all I heard, the drug definitely worked, but the question was framed differently.”
The FDA posed the question to this committee not by asking if the drug worked or not, but by asking about the process of the clinical trial. Did it have enough people? Was it conducted in the normal way? The drug’s trial, of course, did not meet the FDA’s normal standards, but only because it was not treating a normal condition.
Had the FDA utilized the various tools and authorities FDASIA grants to them to ease the evaluation of rare disease treatments, the committee very well may have reached a different conclusion. Instead, these patients and families are on the verge of losing access to the drug.
my point is, ur giving these people too much credit. If a person enlisted, it doesnt necessarily mean they were willling to die for this country.... most men enlist because its the best financial situation for them, so i wouldnt go around saying that they were willing to risk their lives for thsi country. They were willing to risk their lives for financial reasons is more accurate.
thats the one people are referring to. It;s just that Barrons is released today officially so they are trying to act as if its new.
whether it is justified or not, some people were actually expecting new news on the CC and i told the we wouldnt get it. So I expect a drop in the early pm and noon hours, i hope it recovers.
More News. Seems like everyday we get positive news.
Sentiment: Strong Buy
there is no material info though. They already told us all they had on the press release. The shareholder conference call is just part of process , but there wont be any new news on the conf call.
Read this- The financing model of the Company is a bit unique in a sense that the Company has been primarily financed by it CEO Bassam Damaj, who during his tenure as the CEO of Apricus Biosciences (NASDAQ:APRI) took the company from $0.37 to over $5 a share and brought most of the current large pharma partners that company has. Although management financing of the companies is usually a positive thing, in Innovus case it's not because financing is though a line of credit. The disadvantage of a line of credit, the amounts as actual cash on hand can't be reported so in their filings the company reports minimal cash on hand. I am see this as no issue as the company has no going concern from auditors and has been well financed through this line of credit and its revenues. Although investors would want to see a proper raise of funds that will fill the coffers for the company.
This is why you see on the filing that this company as NO GOING CONCERN. The cash on the financials does not represent the true cash they have.
Although if it maintains .30 cents, I will take it
Sentiment: Strong Buy
the cash is not an issue. The CEO puts his own cash toward the business, but that cash on hand cannot be shown on the balance sheet as part of the companys reserves
I dont know if we well hold it, but we should test it.Thoughts and predictions?
Sentiment: Strong Buy